(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07918 A1

(51) International Patent Classification[7]: G01N 33/68, C07K 7/06, A61K 38/08, 39/395

(21) International Application Number: PCT/EP00/06870

(22) International Filing Date: 18 July 2000 (18.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99401841.4 21 July 1999 (21.07.1999) EP

(71) Applicants *(for all designated States except US)*: **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** [FR/FR]; 101 Rue de Tolbiac, F-75654 Paris Cedex 13 (FR). **BAYER PHARMA** [FR/FR]; 13 rue Jean Jaurès, F-92807 Puteaux (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KAVERI, Srinivas** [FR/FR]; 15 rue Lucien et Edouard Gerber, F-92240 Malakoff (FR). **LACROIX-DESMAZES, Sébastien** [FR/FR]; 33 rue de St.Cloud, F-92410 Ville d'Avray (FR). **KAZATCHKINE, Michel** [FR/FR]; 1 rue Le Goff, F-75005 Paris (FR).

(74) Agents: **PORTAL, Gérard** et al.; Cabinet Beau de Loménie, 158 rue de l'Université, F-75340 Paris Cedex 07 (FR).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/07918 A1

(54) Title: CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES

(57) Abstract: The present invention relates to a method of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.